Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Apr 3 2017

Full Issue

Experimental Zika Vaccine Clears Safety Hurdles To Move On To Efficacy Testing

The trial could yield results as early as the end of the year.

Reuters: U.S. Zika Vaccine Begins Second Phase Of Testing

Researchers have begun the second phase of testing of a Zika vaccine developed by U.S. government scientists in a trial that could yield preliminary results as early as the end of 2017. Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases, said on Friday the $100 million trial has already been funded and will proceed, irrespective of the $7 billion in cuts to the National Institutes of Health budget proposed by the Trump Administration over the next 18 months. (Steenhuysen, 3/31)

The Washington Post: Zika Vaccine Test Moves To Next Stage With More Than 2,000 Volunteers In U.S., Abroad

The experimental vaccine, developed by scientists at the National Institute of Allergy and Infectious Diseases, is one of the first to progress to expanded testing of at least a half-dozen candidates in the development pipeline in the United States. Initial results could be available by the end of this year. If this next phase shows good results, and another outbreak of Zika flares in South America or elsewhere, it’s possible that the Food and Drug Administration could make the vaccine available on an emergency basis, said NIAID Director Anthony Fauci in a conference call with reporters. (Sun, 3/31)

Stat: Scientists Begin Mid-Stage Trial Of Zika Vaccine For First Time

Fauci acknowledged public interest in Zika has waned. But he said it is critical to pursue the development of the vaccine. It is likely the Zika virus has become or will become entrenched in parts of the Americas, Fauci said, and thus will continue to pose a risk to pregnant women who may be exposed to it. (Branswell, 3/31)

Meanwhile —

The Hill: Health Officials Brace For Return Of Zika

Florida officials and federal public health experts are keeping a careful eye on the mosquito population in Miami ahead of what they fear will be a breakout year for Zika, a virus that has already infected more than 5,100 people in the United States. The Sunshine State is ground zero for transmissions of the mosquito-borne virus that happen on American soil. While the vast majority of people infected with Zika caught it while traveling abroad, all but six of the 222 confirmed cases acquired within the United States have been in Florida. The other six cases were acquired around Brownsville, Texas. (Wilson ,4/2)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, July 2
  • Wednesday, July 1
  • Tuesday, June 30
  • Monday, June 29
  • Friday, June 26
  • Thursday, June 25
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF